Product Description
VLA15 is currently the only active vaccine program in clinical development against Lyme disease.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: Valneva
Clinical Description
Countries in Clinic: Canada, Finland, Germany, Netherlands, Poland, Sweden, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Lyme Disease
Phase 2: Borrelia Infections|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VALOR | P3 |
Active, not recruiting |
Lyme Disease |
2025-12-26 |
25% |
| C4601012 | P3 |
Active, not recruiting |
Lyme Disease |
2025-06-06 |
25% |
| 2021-005427-20 | P3 |
Active, not recruiting |
Lyme Disease |
2024-12-13 |
|
| VLA15-221 | P2 |
Active, not recruiting |
Borrelia Infections|Lyme Disease |
2022-03-25 |